This thread's no fun without Stoney's weekend muses. Hey Stoney! I was watching something the other day and do you know in the 1990's that the Chinese government actually did a national search for what they called "psychic savants"? Apparently they screened a lot of people, but they actually found nearly 100 (out of a billion people I guess) whose abilities were explainable. You did call CRM You did call NFLX You did call FB And you certainly called SNAP. Ahhhh... don't let it go to your head.
CIA Document Highlights The Reality of “China’s Psychic Children” ".....Tang Yu was reluctant to share his discovery with Tang Keming, his fifty-year-old peasant father. He knew his claim would sound like a lie. Instead, he began to play guessing games with the villagers. He asked them to write random characters on pieces of paper, crumple the paper into balls, and let him hold each ball in turn next to his ear. Tang then guessed the message within, his guesses, always proved right. Word of the boy spread beyond his small town to all the Sichuan province in central China. Soon the region’s science commission and its bureau of education and culture had asked to examine Tang, and researchers there confirmed his ability to identify words and colours on small wads of paper held to his ear. News reporters and awe-struck officials of the Sichuan Provincial Party Committee quickly backed those results, and on March 11, 1979, this remarkable tale was published in Sichuan Daily." https://sarahwestall.com/cia-document-highlights-the-reality-of-chinas-psychic-children/ hmmmm.
Hey All I am licking my wounds from OCUL. Still working through the situation it's not good for me because so many letters that sound the same but a different freakin' eye drop solution it looks like good saftey profile didn't meet endpoint shouldn't effect what they have on the market already and the compound we are following in the pipeline has their trial coming up still -- I don't see any read out here that says this one fails that one fails. Man what a kick in the ass... The eye business looks tougher than I thought . Another company had the same news today but I bet they only go down 6% why OCUL got mashed the way it did is hard to say... there must of been more upside here than I even imagined and that all got turned upside down. Accuray Incorporated (ARAY) NasdaqGS - NasdaqGS Real Time Price. Currency in USD 4.3700+0.3100 (+7.64%)<------------ At close: October 22 4:00PM EDT 4.5900 +0.22 (+5.03%)<----------- If you stay up late at night and listen to the radio you may hear an ad for Cyberknife.. It sounds pretty good hardly any side effects and they cyber Knife that tumor out. A) Accuray's CyberKnife platform shows breast cancer survival improvement in study 07:39 ARAY Accuray announced that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation delivered using the Accuray CyberKnife robotic radiotherapy platform. Study investigators performed complex modeling that also indicates the survival rate could be better with CyberKnife APBI than other radiation delivery approaches. The CyberKnife platform is equipped with artificial intelligence-driven motion synchronization technology, Synchrony, that adjusts the radiation beam to the patient or tumor movement, keeping on target throughout the treatment, reducing patient burden. B) Accuray to hold analyst & investor meeting 00:00 ARAY Here is a company doing it the right way--the news is good and they happen to have an analyst day..... ARAY GUMMY POSSIBILITIES
ARAY does not have much coverage. They did recently beat earn- Accuray raises FY22 revenue view to $420M-$427M from $410.0M-$420.0M 16:08 ARAY Consensus for FY22 revenue is $415.82M.
Perficient price target raised to $150 from $115 at Maxim 08:11 PRFT Maxim analyst Jack Vander Aarde raised the firm's price target on Perficient to $150 from $115 and keeps a Buy rating on the shares ahead of its Q3 results. The analyst is citing the company's recent accretive acquisitions of Talos Digital and Izmul S.A. while also calling for an over 10% multi-year organic revenue growth. The stock is up about 160% year-to-date but its 32.4-times earnings multiple is still a discount relative to peers' 41.5-times, Vander Aarde tells investors in a research note. PRFT has been around along time now. I'm surprised they have never been approached for a buy out. About ten years ago this was a very hot name. This PT hike is hefty... PRFT<---------
BAD NEWS FOR THIS EYE CO-->#1 Eyenovia announces FDA reclassification of MydCombi 08:09 EYEN Eyenovia announced that MydCombi, the company's proprietarycombination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device combination product by the U.S. Food and Drug Administration in a Complete Response Letter for the company's new drug application received on October 22, 2021. Eyenovia will provide additional information to the FDA, as requested in the CRL, as soon as possible, including information necessary to meet additional requirements under Genus Medical Technologies, LLC v. FDA. Genus refers to a recent decision by the U.S. Court of Appeals for the District of Columbia Circuit which has resulted in an agency-wide reclassification by FDA of certain drugs to devices or to drug-device combination products. There were no issues raised related to the phase III clinical program for MydCombi. "While we were surprised by the FDA's position in the CRL, given our original FDA designation, we understand the unusual situation created by the impact of the Genus case, which compelled an Agency-wide reclassification," stated Dr. Sean Ianchulev, CEO and CMO of Eyenovia. "Fortunately, we had taken actions throughout the development of MydCombi to minimize the impact of a potential reclassification by the FDA.
Hertz orders 100,000 cars from Tesla, Bloomberg reports » 07:49 HTZZ, TSLA HUGE.! No Turning Back Now From EV Gol Linhas initiated with an Overweight at Barclays 05:22 GOL Whoever is the eye guy at the FDA is tough as hell. Bad New For This eye Company #2 Erytech Pharma announces TRYbeCA-1 trial misses OS primary endpoint 05:22 ERYP Erytech Pharma announced top-line results from its Phase 3 TRYbeCA-1 clinical trial evaluating eryaspase as second-line treatment in 512 patients with metastatic pancreatic cancer. The trial did not meet its primary endpoint of overall survival, or OS. In the TRYbeCA-1 trial, eryaspase demonstrated an improvement in the primary endpoint of OS compared to chemotherapy alone with a hazard ratio, or HR, of 0.92 in the intent-to-treat population, and the difference was not statistically significant. Same exact news as OCUL why do I think these guys aren't going to get punished the same way? Who Got it right?- Clearside. ->Bausch + Lomb, Clearside Biomedical announce FDA approval of Xipere 06:50 BHC, CLSD CLSD Possible Gummy #2 Ocular Therapeutix price target lowered to $14 from $18 at H.C. Wainwright 06:15 OCUL H.C. Wainwright analyst Yi Chen lowered the firm's price target on Ocular Therapeutix to $14 from $18 and reiterates a Buy rating on the shares after OTX-CSI did not meet the primary endpoint in Phase 2 dry eye trial. However, OTX-CSI demonstrated a favorable safety profile, says the analyst, who does not believe the data portend an unsatisfactory readout from the Phase 2 trial of OTX-DED for the short-term treatment of dry eye disease, which is slated to occur in Q1 of 2022. So annoying. ) ) )
2 Interesting companies.) ) ) ) I've been thinking more and more about 3D Printing. This is a way to start manufacturing in America again and help with the supply chain issue. Already you can print a small house. I don't belive this co is a 3D printing company but they seem like they would be involved... Shapeways initiated with a Buy at Stifel 05:34 SHPW Five9 upgraded to Overweight from Sector Weight at KeyBanc 05:18 I heard a guy ion the TV who was smart. And he recommended FIVE and I got all excited because I own Five Below the retailer.. But of course he was talking about another Five. He made it sound really good--- FIVN, ZM KeyBanc analyst Michael Turits upgraded Five9 (FIVN) to Overweight from Sector Weight with a $200 price target following survey data and discussions with channel partners. The analyst sees Five9 as one of the best positioned names in communications software. Partners see a durable CX modernization trend and the company gaining share, Turits tells investors in a research note. He views the near-term disruption from the failed Zoom Video (ZM) merger as a buying opportunity.<---------- Zoom Video Van... I feel very confident that FIVN is a good buy. Maybe a FIVE for FIVE swap!
CIA Document Highlights The Reality of “China’s Psychic Children” Well they have shot off two hypersonic weapons. & These UFO's that have been buzzing us they may be advanced Chinese Drones. What is this all leading to?